Compare ACT & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACT | TGTX |
|---|---|---|
| Founded | 1981 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 7.9B |
| IPO Year | 2021 | 2008 |
| Metric | ACT | TGTX |
|---|---|---|
| Price | $49.19 | $54.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $44.25 | ★ $49.80 |
| AVG Volume (30 Days) | 305.7K | ★ 2.2M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | 3.43 | ★ 1746.67 |
| EPS | ★ 2.42 | 0.17 |
| Revenue | ★ $1,235,827,000.00 | $2,785,000.00 |
| Revenue This Year | $4.06 | $49.08 |
| Revenue Next Year | $2.33 | $26.69 |
| P/E Ratio | ★ $20.30 | $297.41 |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $34.64 | $26.76 |
| 52 Week High | $50.56 | $59.30 |
| Indicator | ACT | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.57 | 59.92 |
| Support Level | $41.97 | $51.22 |
| Resistance Level | N/A | $58.08 |
| Average True Range (ATR) | 0.88 | 2.10 |
| MACD | -0.08 | 0.39 |
| Stochastic Oscillator | 69.91 | 80.70 |
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The company operates in a single reportable segment namely Mortgage Insurance The principal mortgage insurance customers are originators of residential mortgage loans that determines the mortgage insurer or insurers to be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.